Xvivo Perfusion: And the beat goes on - Redeye

Redeye argues that the negative YTD share price performance does not reflect Xvivo’s underlying fundamental developments. We see a doubling potential in the share for this emerging niche leader in the coming 12 months, driven by strengthening sentiment and several near-term catalysts.

Länk till analysen i sin helhet: https://www.redeye.se/research/1133624/xvivo-perfusion-and-the-beat-goes-on?utm_source=finwire&utm_medium=RSS